Abeona Therapeutics
ABEO
83 hedge funds and large institutions have $126M invested in Abeona Therapeutics in 2020 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 35 increasing their positions, 21 reducing their positions, and 9 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 21
33% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 9
4% more funds holding
Funds holding: 80 → 83 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.31% less ownership
Funds ownership: 53.21% → 51.9% (-1.3%)
13% less call options, than puts
Call options by funds: $198K | Put options by funds: $227K
17% less capital inflows, than outflows
Capital inflows: $8.02M | Capital outflows: $9.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.73M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$691K |
| 3 |
BlackRock
New York
|
+$650K |
| 4 |
Woodline Partners
San Francisco,
California
|
+$546K |
| 5 |
Los Angeles Capital Management
Los Angeles,
California
|
+$404K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Perceptive Advisors
New York
|
-$3.06M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.55M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.59M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
-$671K |
| 5 |
Pura Vida Investments
New York
|
-$391K |
ABEO Hedge Fund Activity: Q2 2020 in Review
83 of the 4,890 institutional investors tracked by Wall St. Rank reported a position in Abeona Therapeutics (ABEO) for Q2 2020, worth a combined $126M — up 35% from $93.4M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ABEO positions and 9 closed out — a net gain of 3 holders — while 35 added to existing stakes and 21 trimmed.
The largest buyer was Millennium Management, adding an estimated $1.73M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $3.06M sold.
- 83 institutional investors held Abeona Therapeutics (ABEO) as of Q2 2020, up from 80 in Q1 2020.
- Funds reported $126M of Abeona Therapeutics stock for Q2 2020, up 35% quarter-over-quarter.
- 12 funds opened new Abeona Therapeutics positions in Q2 2020 and 9 closed out, a net change of +3 holders.
- The largest Abeona Therapeutics buyer in Q2 2020 was Millennium Management, an estimated $1.73M added.
- The largest Abeona Therapeutics seller in Q2 2020 was Perceptive Advisors, an estimated $3.06M sold.
Based on aggregated 13F filings for Q2 2020.